Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001306503 | SCV001495878 | likely benign | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2025-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004034099 | SCV004887963 | uncertain significance | Inborn genetic diseases | 2024-02-06 | criteria provided, single submitter | clinical testing | The c.2602C>T (p.R868C) alteration is located in exon 17 (coding exon 16) of the INF2 gene. This alteration results from a C to T substitution at nucleotide position 2602, causing the arginine (R) at amino acid position 868 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |